Search Results
Apr 21, 2026, 16:53 ET GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
February 2026. The NHS-Galleri trial, the first and only randomized controlled study of an MCED test, was designed to demonstrate population-level impact through the reduction of late-stage cancer diagnosis and increased cancer detection rate within England's National Health Service (NHS). The trial evaluated
More news about: GRAIL, Inc.
Apr 21, 2026, 11:05 ET New Research: AI Deployment in the Digital Workplace Constrained by Fragmented Knowledge Systems
enterprise-grade security and governance, Simpplr is designed to scale across complex organizations. More than 1,000 organizations — including AAA, the NHS, Penske, and Moderna — trust Simpplr to empower a connected, productive workforce. Learn more at
More news about: Simpplr
Apr 21, 2026, 03:02 ET Six London NHS Trusts move to Sectra's enterprise imaging as a cloud service to strengthen cybersecurity and patient care
Sectra (STO: SECT B) has signed a contract to deliver its enterprise imaging solution as a fully managed cloud service, Sectra One Cloud, to six NHS Trusts within the north central area of London, which provides care to approximately 1.4 million people. The six Trusts, four of which already
More news about: Sectra
Apr 20, 2026, 18:00 ET NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES FINAL RESULTS OF RIGHTS OFFERING
NEW YORK, April 20, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced today the final results of its transferable rights offering (the "Offer"), which expired at 5:00 P.M. Eastern Time on April
More news about: Neuberger Berman
Apr 20, 2026, 11:05 ET History repeating as water systems become casualties of modern war, warns Hydrachem
and help produce billions of litres of safe drinking water each year. The company also partners with leading healthcare institutions, including the NHS, alongside global aid and public health organisations.Hydrachem supplies sectors including healthcare, hospitality, manufacturing, food preparation
More news about: Hydrachem
Apr 17, 2026, 18:01 ET 歐洲臨床微生物學與感染病學會大會 (ESCMID Global)：英國衛生安全局 (UKHSA) 重大研究發現，孕婦接種呼吸道合胞病毒 (RSV) 疫苗可將嬰兒住院風險降低逾八成
日推出全國孕婦 RSV 疫苗接種計劃，為懷孕滿 28 週的孕婦提供二價融合前 F 蛋白 (Bivalent Prefusion F) 疫苗。為評估該疫苗對與 RSV 相關的下呼吸道感染所致嬰兒住院的影響，英國衛生安全局的研究人員利用全國連結數據集進行回顧性隊列研究，數據涵蓋英國國民保健署 (NHS) 產科紀錄、疫苗接種資料，以及醫院及實驗室數據。 分析涵蓋 2024 年 9 月 2 日至 2025 年 3 月 24 日期間出生的 289,399 名嬰兒，佔該期間英格蘭出生人口總數的 90%。在研究樣本中，共錄得 4,594 宗與 RSV 相關的住院個案。 儘管未接種疫苗母親所生的嬰兒僅佔總樣本的
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID 글로벌: 영국 보건안전청 대규모 연구, 산모 RSV 백신 접종이 영아 입원 위험을 80% 이상 감소시킨다는 결과 발표
2가 프리퓨전 F 백신(Bivalent Prefusion F vaccine)을 제공하고 있다.RSV 관련 하기도 감염으로 인한 영아 입원에 미치는 영향을 평가하기 위해 영국 보건안전청(UK Health Security Agency, UKHSA) 연구진은 NHS 산부인과 기록, 예방 접종 데이터, 병원 및 실험실 데이터 등 연계된 국가 데이터 세트를 활용한 후향적 코호트 연구를 수행했다. 분석에는 2024년 9월 2일부터 2025년 3월 24일 사이에 태어난 28만 9399명의 영아가 포함되어 있으며, 이는 해당 기간 영국
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
RSV-associated LRTI, researchers from the UK Health Security Agency (UKHSA) conducted a retrospective cohort study using linked national datasets, including NHS maternity records, immunisation data and hospital and laboratory data. The analysis included 289,399 infants born between 2 September 2024 and 24 March
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
RSV-associated LRTI, researchers from the UK Health Security Agency (UKHSA) conducted a retrospective cohort study using linked national datasets, including NHS maternity records, immunisation data and hospital and laboratory data. The analysis included 289,399 infants born between 2 September 2024 and 24 March
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID Global: RSV-Impfung während der Schwangerschaft senkt das Hospitalisierungsrisiko bei Säuglingen um mehr als 80 Prozent, wie eine große UKHSA-Studie zeigt
Forscher der UK Health Security Agency (UKHSA) eine retrospektive Kohortenstudie anhand verknüpfter nationaler Datensätze durch, darunter NHS-Schwangerschaftsdaten, Impfdaten sowie Krankenhaus- und Labordaten. Die Analyse umfasste 289 399 Säuglinge, die zwischen dem 2. September 2024 und dem 24. März
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID Global: vacinação materna contra o VSR reduz o risco de hospitalização infantil em mais de 80%, revela importante estudo da UKHSA
Security Agency (UKHSA) realizaram um estudo de coorte retrospectivo usando conjuntos de dados nacionais vinculados, incluindo registros de maternidade do NHS, dados de imunização e dados hospitalares e laboratoriais. A análise incluiu 289.399 bebês nascidos entre 2 de setembro de 2024 e 24 de março de 2025,
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID Global: La vacunación materna contra el VSR reduce el riesgo de hospitalización infantil en más del 80 %, según un importante estudio de UKHSA
(UKHSA) realizaron un estudio de cohorte retrospectivo utilizando conjuntos de datos nacionales vinculados, incluidos los registros de maternidad del NHS, los datos de inmunización y los datos hospitalarios y de laboratorio. El análisis incluyó a 289.399 bebés nacidos entre el 2 de septiembre de 2024 y
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET La vacunación materna contra el VRS reduce el riesgo de hospitalización infantil en más del 80%
de cohortes retrospectivo utilizando conjuntos de datos nacionales vinculados, incluidos los registros de maternidad del Servicio Nacional de Salud (NHS), datos de vacunación y datos hospitalarios y de laboratorio. El análisis incluyó a 289.399 bebés nacidos entre el 2 de septiembre de 2024 y el 24 de
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID Global : la vaccination maternelle contre le VRS réduit de plus de 80% le risque d'hospitalisation des nourrissons, selon une importante étude de l'UKHSA
sanitaire (UKHSA) ont mené une étude de cohorte rétrospective en utilisant des ensembles de données nationales, notamment les dossiers de maternité du NHS, les données de vaccination et les données hospitalières et de laboratoire. L'analyse a porté sur 289 399 nourrissons nés entre le 2 septembre 2024 et
More news about: ESCMID Global
Apr 17, 2026, 08:00 ET Ultima Genomics releases groundbreaking TRACERx MRD data showing ppmSeq performance and unveils clinical progress of whole genome sequencing at inaugural global MRD Symposium at AACR 2026
a broader patient population will give us the statistical power and clinical context to determine how whole genome MRD monitoring can be deployed at NHS scale and beyond.""The ability to perform personalized, tumor-guided ctDNA detection at parts-per-million sensitivity — without bespoke panel
More news about: Ultima Genomics
Apr 16, 2026, 11:05 ET Simpplr Report: Internal Communications Has Proven Its Value but Is Running Out of Room to Scale
helps organizations cut through noise and deliver relevant communications employees actually rely on. More than 1,000 organizations — including AAA, the NHS, Penske, and Moderna — trust Simpplr to keep their workforce informed, aligned, and engaged. Learn more at
More news about: Simpplr
Apr 16, 2026, 08:30 ET NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES PRELIMINARY RESULTS OF RIGHTS OFFERING
NEW YORK, April 16, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced today the preliminary results of its transferable rights offering (the "Offer"), which commenced on March 23, 2026 and
More news about: Neuberger Berman
Apr 15, 2026, 09:00 ET GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL,
More news about: Levi & Korsinsky, LLP
Apr 15, 2026, 08:00 ET Marking Five Years of Success, the Starts Hear National Awareness Campaign Begins Its Sixth Year of Educating Families About the Newborn Hearing Screening
awareness campaign. Starts Hear is a public health awareness campaign informing expectant parents about the importance of the newborn hearing screening (NHS) and what to do in the event of a failed screening.
More news about: Hearing First
Apr 15, 2026, 03:00 ET Cepheid and Oxford Nanopore Expand Partnership Following Successful Phase One Collaboration
emerging strains," said Dr. Rahul Batra, Deputy Director of the Centre for Clinical Infection & Diagnostics Research (CIDR) at Guy's and St Thomas' NHS Foundation Trust. "We're excited to collaborate with Cepheid and Oxford Nanopore to explore faster and more streamlined approaches that could make
More news about: Cepheid and Oxford Nanopore Technologies
Apr 14, 2026, 09:00 ET The Galien Foundation Announces 2026 Galien UK Forum - Future Health Disrupted: From Discovery to Delivery
meaningful advances in healthcare," said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics, Chair of the Galien UK Committee. "This year's theme and discussions will not only celebrate scientific excellence, but
More news about: The Galien Foundation
Apr 13, 2026, 08:39 ET NHS Concept to Commerce Makes a Strong Debut, Driving Innovation and Growth
NHS Concept to Commerce. Evolving from its 80-year show success roots as the National Hardware Show, this reimagined NHS Concept to Commerce event has officially shifted the paradigm from a traditional trade
More news about: NHS Concept to Commerce
Apr 13, 2026, 03:01 ET Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
pneumonia. The Lancet.10 Gregg E. et al. 2025. Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspective. JAC-Antimicrobial Resistance.11 Bachur R.G. et al. 2024. A rapid host-protein test for differentiating bacterial from viral infection:
More news about: Beckman Coulter Diagnostics
Apr 10, 2026, 13:56 ET Apomeds Enters the UK Market With Its Digital Healthcare Platform
$18.7billion in 2035. A number of drivers have been posited for this growth, including ongoing NHS digitization and increased patient demand for alternative treatment methods. Overall, these dynamics point toward an attractive opportunity for healthcare
More news about: Apo Global Ltd.
Apr 10, 2026, 08:00 ET Erayak Announces Strategic Evolution into U.S.-Centric Energy Solutions Leader; Unveils Tri-Fuel & UPS Innovations Following 2026 NHS Success
emergency energy solutions, today announced a major strategic pivot following its high-impact showcase at the 2026 National Hardware Show (NHS) and an exhaustive 5,000-mile research tour across the United States. Spanning California, Arizona, Texas, Florida, and New York, this mission has
More news about: Erayak Power Solution Group Inc.